ERBB2 and neoplasm: Our work builds on tumor-specific imaging by targeting surface Hsp90 expression, which is ubiquitous to all receptor subtypes of cancer, increasing the potential population target from only Her2+ tumors (~20% of breast cancer diagnoses) to all patients with breast cancer.